In This Section

choip [at]
Location - People View
Room 4010

3501 Civic Center Blvd
Philadelphia, PA 19104
United States

Research Topics
Peter S. Choi, PhD
Peter S. Choi Headshot

Dr. Choi's research focuses on the role of RNA-binding proteins in the regulation of alternative splicing and how mutations in these factors contribute to cancer. He uses a combination of genetically-engineered models and high-throughput approaches to better understand how alternative splicing influences cellular function and to identify potential opportunities for therapeutic intervention.



Subscribe to be notified of changes or updates to this page.


Alternative splicing is an essential mode of gene regulation that greatly diversifies the coding potential of the transcriptome. However, this process is often dysregulated in human cancer. For example, mutations in splicing regulatory sequences can affect specific RNA transcripts and result in the expression of oncogenic protein products. In addition, recent large-scale genomic surveys of multiple cancer types have identified somatic alterations in splicing factors and other RNA-binding proteins, demonstrating that more global changes in RNA processing can also play a significant role in tumorigenesis. Despite the ability to comprehensively detect the landscape of alternatively spliced transcripts through next-generation sequencing, it has remained difficult to predict much of the functional impact of aberrant splicing.

Dr. Choi's group aims to decipher how patterns of alternative splicing control cellular processes and, when perturbed, can lead to pathogenic states such as cancer. He is particularly interested in characterizing RNA-binding proteins known to be mutated in cancer and their functional role in alternative splicing and other steps in RNA processing.

Dr. Choi and his team are also interested in understanding how the expression of specific isoforms may regulate fundamental pathways involved in cell division and cell death. To elucidate these questions, they make extensive use of genome editing to engineer faithful models of cancer-associated mutations, and custom high-throughput screening approaches to more rapidly characterize the function of alternatively spliced isoforms. Dr. Choi hopes to translate the wealth of genomic data and ever-evolving experimental tools into meaningful biological insights and more effective treatments for cancer.

Dr. Choi's notable career achievements include:

  • NIH Pathway to Independence Award
  • Ruth L. Kirschstein NRSA Individual Postdoctoral Fellowship Award
  • International Association for the Study of Lung Cancer (IASLC) Fellowship Award


Education and Training

BS, Cornell University (Biology/Biochemistry), 2002

PhD, Stanford University (Immunology), 2012

Fellowship, Stanford University (Cancer Biology), 2012

Fellowship, Dana-Farber Cancer Institute (Cancer Biology), 2018

Titles and Academic Titles


Assistant Professor of Pathology and Laboratory Medicine

Professional Memberships

American Association for Cancer Research, 2007-

Professional Awards

International Association for the Study of Lung Cancer Fellowship Award, 2013-2015

Ruth L. Kirschstein NRSA Individual Postdoctoral Fellowship Award, 2015-2016

Pathway to Independence Award, 2016-2018

Publication Highlights

Li J, Choi PS, Chaffer CL, Labella K, Hwang JH, Giacomelli AO, Kim JW, Ilic N, Doench JG, Ly SH, Dai C, Hagel K, Hong AL, Gjoerup O, Goel S, Ge JY, Root DE, Zhao JJ, Brooks AN, Weinberg RA, Hahn WC. An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. Elife. 2018 Jul; 7. pii: e37184. PMID: 30059005
Zhang X, Choi PS, Francis JM, Imielinski M, Watanabe H, Cherniack AD, Meyerson M. Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nat Genet. 2016 Feb; 48(2):176-82. PMID: 26656844
Choi PS, Li Y, Felsher DW. Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance. Proc Natl Acad Sci USA. 2014 Aug; 111(32):E3316-24. PMID: 25071175
Choi PS and Meyerson M. Targeted genomic rearrangements using CRISPR/Cas technology. Nat Commun. 2014 Apr; 5:3728. PMID: 24759083
Choi PS, van Riggelen J, Gentles AJ, Bachireddy P, Rakhra K, Adam SJ, Plevritis SK, Felsher DW. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proc Natl Acad Sci USA. 2011 Oct; 108(42):17432-7. PMID: 21969595